Nomelcitinib (D-2570) vs zasocitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Nomelcitinib (D-2570)
Developed by InventisBio
NCT06278350 · Phase 2 · completed
The study randomized 161 participants with moderate to severe plaque psoriasis to three D-2570 dose groups or placebo, with participants, care providers and investigators masked. The primary endpoint, PASI 75 at week 12, was met in all three dose groups versus placebo (at least 85% vs 12.5%, p<0.001), per the sponsor's release and the peer-reviewed publication. The trial is mid-sized and 12 weeks long, so durability and safety beyond week 12 are not established.
Next expected readout: July 2027 · NCT07326813 (registry estimate)
Reported efficacy
Percentage of subjects with at least 75% improvement in PASI (Day 1-Day 85): Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) (met)
Result source: NCT06278350
zasocitinib
Developed by Takeda Pharmaceutical Company
NCT06108544 · Phase 3 · completed
This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT07752108 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)
Result source: NCT06973291
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Nomelcitinib (D-2570) | zasocitinib |
|---|---|---|
| PASI 75 | —Trial running · NCT07130604 | 67.3% vs 5.8%+61.5 vs placeboNCT049998394 other results
|
| PASI 90 | —Trial running · NCT07130604 | 46.2% vs 0%+46.2 vs placeboNCT049998393 other results
|
| PASI 100 | —Trial running · NCT07130604 | 32.7% vs 0%+32.7 vs placeboNCT049998393 other results
|
| sPGA 0/1 | —Trial running · NCT07130604 | 51.9% vs 3.8%+48.1 vs placeboNCT049998395 other results
|
| DLQI, change | —Trial running · NCT07130604 | -8.9 vs -4.9−4 vs placeboNCT049998393 other results
|
PASI 75
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- zasocitinib
- 67.3% vs 5.8%+61.5 vs placeboNCT04999839
4 other results
- 67.9% vs 5.8% NCT04999839
- 44.2% vs 5.8% NCT04999839
- 18% vs 5.8% NCT04999839
- 75.7% vs 12.1% NCT06088043
PASI 90
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- zasocitinib
- 46.2% vs 0%+46.2 vs placeboNCT04999839
3 other results
- 45.3% vs 0% NCT04999839
- 21.2% vs 0% NCT04999839
- 8% vs 0% NCT04999839
PASI 100
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- zasocitinib
- 32.7% vs 0%+32.7 vs placeboNCT04999839
3 other results
- 15.1% vs 0% NCT04999839
- 9.6% vs 0% NCT04999839
- 2% vs 0% NCT04999839
sPGA 0/1
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- zasocitinib
- 51.9% vs 3.8%+48.1 vs placeboNCT04999839
5 other results
- 49.1% vs 3.8% NCT04999839
- 26.9% vs 3.8% NCT04999839
- 10% vs 3.8% NCT04999839
- 69.2% vs 12.6% NCT06108544
- 71.4% vs 10.7% NCT06088043
DLQI, change
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- zasocitinib
- -8.9 vs -4.9−4 vs placeboNCT04999839
3 other results
- -8.5 vs -4.9 NCT04999839
- -7.9 vs -4.9 NCT04999839
- -5.3 vs -4.9 NCT04999839
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Nomelcitinib (D-2570): 0 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | zasocitinib |
|---|---|
| Dropout rate | 9.6%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results13.2%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 13.5%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 16%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.9%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 1.9%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 2%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 30 mga covid-19 13.5% (placebo 1.9%) blood creatine phosphokinase increased 5.8% (placebo 3.8%) dermatitis acneiform 5.8% (placebo 0%) NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results15 mg covid-19 11.3% (placebo 1.9%) acne 5.7% (placebo 0%) blood creatine phosphokinase increased 5.7% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 5 mg covid-19 7.7% (placebo 1.9%) lymphocyte count decreased 5.8% (placebo 0%) blood creatine phosphokinase increased 3.8% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 2 mg covid-19 12% (placebo 1.9%) alanine aminotransferase increased 6% (placebo 0%) diarrhoea 6% (placebo 1.9%) NCT04999839 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
zasocitinib
show 4 more results
show 5 more results
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nomelcitinib (D-2570)'s landscape · zasocitinib's landscape